NasdaqGM:VCELBiotechs
Vericel (VCEL) Is Down 7.0% After Issuing 2025 Revenue And Profitability Guidance - Has The Bull Case Changed?
Vericel Corporation recently issued preliminary, unaudited guidance for the fourth quarter and full year 2025, pointing to 23% quarterly revenue and MACI sales growth and approximately US$276,000,000 in total net revenue, alongside GAAP net income profitability for a second consecutive year.
This combination of double-digit top-line expansion and repeat GAAP profitability suggests the company’s regenerative therapies model is scaling operationally as it grows.
With Vericel highlighting 23%...